ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年04月28日 09時00分
Source:
Eisai
エーザイ、Institutional Investor誌の「The All-Japan Executive Team」において、「Most Honored Company」およびセクター第1位に選出
東京, 2020年04月28日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、米国金融情報誌「Institutional Investor」がこのたび発表した「The All-Japan Executive Team」のBiotechnology & Pharmaceuticalsセクターにおいて、「Best CEOs」「Best CFOs」でそれぞれ第1位となり、「Most Honored Company」およびセクター総合第1位に選定されたことをお知らせします。
本調査は、世界的に著名な金融情報誌である「Institutional Investor」が、世界の機関投資家やアナリストの投票をもとに優れたIR活動を行う日本企業をセクターごとに選出するランキングです。2020年は、189の機関に所属する約350名の投資家・アナリストが投票を行いました。当社は、投資家説明会をはじめとする高質なIR活動や、ESGへの積極的な取り組みなどが高い評価を受けるとともに、CEO内藤 晴夫が、信頼性、コミュニケーションの質、リーダーシップで高く評価されました。
詳細は、「Institutional Investor」誌ホームページをご参照ください。(英語)www.institutionalinvestor.com/research/9955/the-all-japan-executive-team
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念に定めています。当社は、この理念の実現のため、株主・投資家の皆様の権利を尊重し、経営の公正性・透明性を確保し、企業価値向上の一助となるIR活動に取り組んでまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202019.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 00:23 JST
Honda to Begin Sales of Super-ONE Compact EV
May 22, 2026 00:16 JST
Fujitsu supports the Panasonic Group in accelerating its sustainability management through the implementation of a CFP calculation solution
May 21, 2026 13:57 JST
Sharp Launches Poketomo Conversational AI Character in Taiwan
May 21, 2026 13:55 JST
Hitachi Energy's HMAX Energy service solutions strengthen long-term reliability for Akaysha Energy's Ulinda Park BESS
May 21, 2026 13:40 JST
Heads of State/Government, Ministers, and Senior Officials from 30 Countries to Convene in Tokyo for the Island States Ocean Summit
May 20, 2026 17:00 JST
Trusco Nakayama and Fujitsu accelerate personnel transfer decision-making process with data and AI
May 20, 2026 13:50 JST
Hitachi announces strategic partnership with Anthropic to strengthen "Lumada 3.0" through frontier AI
May 19, 2026 23:09 JST
SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
May 19, 2026 13:37 JST
Ashikaga Bank launches Fujitsu's service supporting digitalization of Inheritance Procedure
May 18, 2026 18:13 JST
Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST
MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST
MHI Thermal Systems Receives A' Design Awards
-- Recognition at Italy's International Design Competition for the Hydrolution EZY Series of Air-to-Water Heat Pumps and the ZT Series of Residential-Use Air-Conditioners --
May 18, 2026 16:26 JST
Tallgrass and Mitsubishi Power Americas Announce Turbine Allocation for Cheyenne Power Hub
May 18, 2026 15:15 JST
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
May 15, 2026 17:36 JST
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
May 15, 2026 17:12 JST
Fujitsu and IBM Japan formalize collaboration in healthcare sector
May 15, 2026 16:42 JST
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
May 15, 2026 15:24 JST
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
May 15, 2026 15:10 JST
More Latest Release >>
Related Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
More Press release >>